

CANCER REFERRAL FORM FOR CHROMOSOME ANALYSIS

Medical Genetics – Wake Forest University School of Medicine – Winston Salem NC

www.wfubmc.edu/medicalgenetics

Phone: 336-716-4321 Fax: 336-716-2554

Collection Date: _____ Time: _____ am/pm WFU LAB #: _____

Name: _____ / _____ / _____ Sex: male / female
 (Please print) Last First Middle
 Address: _____ / _____ / _____ Daytime Phone: (____) _____
 Mailing Address City State Zip
 Date of Birth: _____ SS#: _____

Hospital and Unit #: _____
 Type of Specimen: Bone Marrow Bone Core Blood FNA Pleural Fluid Lymph node
 Solid tumor (type): _____ Other: _____

COLLECTION TECHNIQUE: Bone marrow is collected using preservative free sodium heparin and placed in lab provided media. Blood is collected in a green stoppered sodium heparin tube. **Keep all samples at room temperature.**

Physician/Provider Order	Statement of Financial Responsibility
Physician: Last, First / Phone/Beeper	I authorize any holder of medical or other information about me to release to my healthcare provider, third party processor, the Centers for Medicare and Medicaid Services or its intermediaries or carriers any information needed for this health care encounter or related claim. I permit a copy of this authorization to be used in place of the original, and request payment of authorized insurance benefits be made on my behalf to the WFU Physicians. I understand I am responsible for payment of these charges. I am also responsible for payment if my insurance carrier decides this is a non-covered service or requires prior authorization, which I did not obtain. Patient Signature: _____ Date: _____
1. _____	
X	
X Physician Signature Required	
2. _____	
3. _____	

Billing Information

Bill: Moses Cone Hospital Moses Cone / Solstas
 Women's Hospt. of Greensboro Wesley Long Hospital Other : _____
 Medicare # _____ Medicaid #: _____ Carolina Access #: _____
 Insurance: _____ Employer: _____ Policy #: _____
 (Enclose copy of both sides of insurance card)

SIGNS/SYMPTOMS/INDICATION (ICD-10 CODES) FOR CHROMOSOME STUDY

Indicate all that apply. Codes here do not represent listing of ICD-10 codes available. Please consult current ICD-10 code book for complete listing.

<input type="checkbox"/> ALL (C91.00) <input type="checkbox"/> remiss (.01) { }B { }T	<input type="checkbox"/> Leukocytosis (D72.89)	<input type="checkbox"/> RCMD (D46.A)
<input type="checkbox"/> Acute leukemia (C92.A0) <input type="checkbox"/> remission (.01)	<input type="checkbox"/> Myeloid Leuk (C92.9)	<input type="checkbox"/> Non-Hodgkin's (C85.80)
) <input type="checkbox"/> Leukemia (C92.90) unspec .	<input type="checkbox"/> Pancytopenia (D61.82)	
<input type="checkbox"/> AML (C92.00) <input type="checkbox"/> remission (.01)	<input type="checkbox"/> Lymphoma (C85.10) unspec.	<input type="checkbox"/> Thrombocytosis (D47.3)
<input type="checkbox"/> APL (C92.40) <input type="checkbox"/> remission (.01)	<input type="checkbox"/> Follicular lymph (C82.00)	<input type="checkbox"/> Thrombocytopenia (D69.6)
<input type="checkbox"/> Anemia (D63.0)	<input type="checkbox"/> Plasma cell leukemia (C90.10)	<input type="checkbox"/> Tumor specify _____
<input type="checkbox"/> Burkitt's Lymphoma (C83.70) unspec.	<input type="checkbox"/> Multiple myeloma (C90.00) <input type="checkbox"/> remis (.01)	<input type="checkbox"/> Sarcoma specify _____
<input type="checkbox"/> CML (C92.10) <input type="checkbox"/> remission (.01)	<input type="checkbox"/> MDS (D46.Z) <input type="checkbox"/> 5q- (D46.C)	<input type="checkbox"/> Transplant (Z94.81)
<input type="checkbox"/> CLL (C91.10)	<input type="checkbox"/> Myelofibrosis (D75.81)	original disease: _____
<input type="checkbox"/> Hodgkin's Lymphoma (C81.0) unspecif. Site	<input type="checkbox"/> PCV (D45)	[] autologous { } male / { } female
<input type="checkbox"/> Myeloproliferative Syndrome (C94.6)	<input type="checkbox"/> Suspected chromosome abn (Q99.8)	[] allogenic
<input type="checkbox"/> Additional ICD-9/ Clinical Information: _____		

Test Requested Note: When ordering tests for which Medicare reimbursement will be sought, it is recommended that the Provider consult any Local Medical Review Policies (LMRP) or National Coverage Decisions (NCD) that may be applicable to the test(s) being ordered. Based on guidance issued in either of these policies it may be necessary to obtain an Advanced Beneficiary Notice (ABN) from the Medicare Patient. For Medicaid and other carriers a signed **Statement of Financial Responsibility** from the patient may be necessary. (See Statement of Financial Responsibility at top of form.)

TEST(s) REQUESTED

Routine Chromosome / karyotype
 (88237, 88262, 88280, 88285)
 STAT Chromosomes (48 hrs.)
 (88237, 88262, 88280, 88285, 88261)
 Routine Chromosome + FISH select →
 (88237, 88262, 88280, 88285, 88271x_ , 88275)
 STAT FISH (24hrs) / Chromosome select →
 (88271x_ , 88275, 88237, 88262, 88280, 88285)
 FISH Only select →
 (88271x_ , 88275)
 Paraffin-embedded slide - FISH select →
 (88271x2, 88275, 88299)

PROTOCOL: CALGB COG
 ECOG SWOG

FISH Specific Probes

<input type="checkbox"/> t(9;22) BCR/ABL	<input type="checkbox"/> t(1;19) PBX1/TCF3	<input type="checkbox"/> Ewings Sarcoma Panel
<input type="checkbox"/> BCR/ABL and ASS	<input type="checkbox"/> +4 /+10 /+17 ALL	<input type="checkbox"/> Her 2 Neu breast
<input type="checkbox"/> inv(16) AML-M4EO	<input type="checkbox"/> 20q- PCV	<input type="checkbox"/> Eosinophilia panel
<input type="checkbox"/> t(12;21) TEL/AML	<input type="checkbox"/> 14q32 IgH	<input type="checkbox"/> Bladder panel
<input type="checkbox"/> t(15;17) PML/RARA	<input type="checkbox"/> CHOP (12q13)	<input type="checkbox"/> CLL
<input type="checkbox"/> t(8;21) AML1/ETO	<input type="checkbox"/> FGFR1 (8p12)	<input type="checkbox"/> mult myeloma panel
<input type="checkbox"/> 11q23 MLL	<input type="checkbox"/> CDKN2A (9p21)	<input type="checkbox"/> Triple Hit lymphoma panel
<input type="checkbox"/> -5/5q MDS / AM	<input type="checkbox"/> inv(3q)	<input type="checkbox"/> t(2;5) ALK/ROS
<input type="checkbox"/> -7/7q MDS / AML	<input type="checkbox"/> inv(14) TCL1	<input type="checkbox"/> t(2;5) ALK Anaplastic
<input type="checkbox"/> +8 AML / MDS	<input type="checkbox"/>	<input type="checkbox"/> t(8;14) Burkitts
<input type="checkbox"/> X/Y BM transplant	<input type="checkbox"/> t(18q21) MALT	<input type="checkbox"/> Burkitts Panel 8;14/8;22/2;8
<input type="checkbox"/> MYC 8q lymphomas	<input type="checkbox"/> 3q abn BCL6	<input type="checkbox"/> 14;18) BCL2 Follicular
<input type="checkbox"/> t(6;9) AML	<input type="checkbox"/>	<input type="checkbox"/> t(11;14) Mantle cell
<input type="checkbox"/> 6q MYB	<input type="checkbox"/> PDGFRB	<input type="checkbox"/> SYT 18 Synovial Sarc
<input type="checkbox"/> 12p (ETV6)	<input type="checkbox"/> PDGFRA/CHIC2/FIPL1	<input type="checkbox"/> liposarcoma MDM2
<input type="checkbox"/> X/Y (transplant)	<input type="checkbox"/>	<input type="checkbox"/> iso 12p

Collection Date: _____ Time: _____ am/pm WFU LAB #: _____

CYTOGENETIC LAB USE ONLY

Name: _____ Lab #: _____

Date Received: _____/_____/_____ Time Received: _____

Additional Specimen Evaluation: _____

Additional Samples Received: DNA: __{ } FRAX FISH other _____**LABORATORY REPORT SUMMARY**

Date culture initiated: _____/_____/_____ Tech: _____

Media: Changs RPMI 1640 RPMI 1640 less folic acidCount _____ (x 0.02) = _____ x 10⁶ cell/ml = _____ ml sample/flask or _____ ml centrifuged sample intoSample type: BM UPB BC FNA Other _____Culture: Direct 24h. 24h+ovnt COL 24h pokeweed 48h. 48h. Pokeweed 72h . 72h.Pokeweed 96h. IL-4**REPORT OF RESULTS / SPECIMEN SUMMARY** Final Preliminary Read Back Date _____ Tech _____

To: _____

KARYOTYPE: 46,XY 46,XXINTERPRETATION: normal male normal female abnormal: _____Additional Studies / Results: NOR C-band R-bandFISH: normal male normal female

Abnormality: _____

- | | | | | | | |
|--|--|--|---------------------------------------|---|-------------------------------|-----------------------------------|
| <input type="checkbox"/> t(9;22) | <input type="checkbox"/> +8 | <input type="checkbox"/> t(15;17) | <input type="checkbox"/> +4 /+10 /+17 | <input type="checkbox"/> inv(16) | <input type="checkbox"/> 20q- | <input type="checkbox"/> t(12;21) |
| <input type="checkbox"/> t(8;21) | <input type="checkbox"/> 11q23abn | <input type="checkbox"/> t(2;5) | <input type="checkbox"/> -5/5q | <input type="checkbox"/> -7/7q | <input type="checkbox"/> 6q- | <input type="checkbox"/> inv(3) |
| <input type="checkbox"/> t(11;14) | <input type="checkbox"/> t(14;18) | <input type="checkbox"/> t(8;14) | <input type="checkbox"/> t(1;19) | <input type="checkbox"/> 11;22 | <input type="checkbox"/> 11q- | |
| <input type="checkbox"/> X/Y BM transplant | | | | | | |
| <input type="checkbox"/> t(18q21) | <input type="checkbox"/> MYC | <input type="checkbox"/> 3q | | | | |
| <input type="checkbox"/> Her 2 Neu breast | <input type="checkbox"/> Bladder panel | <input type="checkbox"/> CLL (17p-/+12/13q-/11q) | | <input type="checkbox"/> MM panel (4p/16q-//13q-/11q/17p) | | |

To: _____ By: _____ Date _____